Atherosclerotic Cardiovascular Disease

Plaque-driven narrowing/hardening of the arteries and its clinical consequences -- coronary heart disease, stroke, and peripheral artery disease -- primarily driven by hyperlipidemia/dyslipidemia and managed with lipid-lowering and antiplatelet/anticoagulant therapy.

Phase 1/2 and later readouts in Atherosclerotic Cardiovascular Disease, in your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

Total attributable cost

$69.5B

$3,494/patient

Drug spend

$22.7B

$1,139/patient

How this is calculated ↗

All severities (2015-2018 NHANES cycle) · US

All assets in Atherosclerotic Cardiovascular Disease

← Cardiovascular & Metabolic